Security key
98419J206
XOMA Royalty Corp - Common Stock, $0.0075 par value (XOMA)
CUSIP: 98419J206
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.0075 par value
- Total 13F shares
- 10,160
- Total 13F value
- $431,800
- Share change
- +4
- SEC-reported price per share
- $42.50
- Number of holders
- 3
- Value change
- +$214
- Number of buys
- 1
- Number of sells
- 1
- Shares outstanding
- 17,536,497
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
XOMA full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
XOMA Royalty Corp SEC filings
XOMA Royalty Corp company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98419J206
Recent filing periods:
Ownership snapshot
Top reported holders of XOMA - XOMA Royalty Corp - Common Stock, $0.0075 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
LIGAND PHARMACEUTICALS INC
Disclosed value leader
LIGAND PHARMACEUTICALS INC
Comparable rows
15/15
Latest evidence
27 Apr 2026
13D/G
13F
Lead comparable stake: 47%
13D/G row: LIGAND PHARMACEUTICALS INC
Showing 1-6 of 15 holder rows.
Quick read
LIGAND PHARMACEUTICALS INC leads the comparable SEC ownership view at 47%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens LIGAND PHARMACEUTICALS INC's linked filing trail.
Comparable ownership
Top 5
LIGAND PHARMACEUTICALS INC
47%
MORGAN STANLEY
14%
FMR LLC
10%
Woodline Partners LP
5.4%
BlackRock, Inc.
5.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC |
13D/G
Ligand Pharmaceuticals Incorporated
|
47%
|
$311,622,505
8,062,678 shares
|
$0 | 27 Apr 2026 |
| MORGAN STANLEY |
13F
13D/G
Company
|
14%
from 13D/G
|
$53,396,665
1,702,157 shares
|
— | 31 Mar 2026 |
| FMR LLC |
13F
13D/G
Company
|
10%
from 13D/G
|
$40,874,300
1,302,974 shares
|
— | 31 Mar 2026 |
| Woodline Partners LP |
13D/G
13F
Company
|
5.4%
|
$24,736,039
640,001 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.4%
from 13D/G
|
$20,293,692
646,914 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.2%
|
$19,244,177
613,458 shares
|
$0 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
10,160
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
85
Q2 2026 holders
3
Holder diff
-82
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend